Uniwersytecki Szpital Kliniczny Nr 2 Pum W Szczecinie — Clinical Trial Site

36 Registered trials

18 Currently recruiting

Organisation

Uniwersytecki Szpital Kliniczny Nr 2 Pum W Szczecinie

Location

Szczecin, Poland

Identifier

ORG-100044770

Address

Ul. Powstancow Wielkopolskich 72, 70-111, Poland

Departments

-
, Klinika Chirurgii Naczyniowej, Ogólnej i Angiologii
II Klinika Okulistyki
Kinika Ginekologii Operacyjnej i Onkologii Ginekologicznej Doroslych i Dziewczat
Klinika Ginekologii Operacyjnej i Onkologii Ginekologicznej Doroslych i Dziewczat
Klinika Ginekologii Operacyjnej i Onkologii Ginekologicznej Dorosłych i Dziewcząt
Klinika Ginekologii Operacyjnej i Onkologii Ginekologicznej Dorosłych i Dziewcząt PUM
Klinika Ginekologii Operacyjneji Onkologii Ginekologicznej Dorosłychi Dziewcząt
Klinika Kardiochirurgii
Klinika Kardiologii
Klinika Kardiologii z Intensywnym Nadzorem Kardiologicznym
Klinika Kardiologii z Intensywnym Nadzorem Kardiologicznym
Klinika Nefrologii, Transplantologii i Chorób Wewnętrznych
Klinika Nefrologii, Trasnplantologii i Chorób Wewnetrznych
Klinika Patologii Noworodka
N/A
NA
Neonatal Pathology Clinics
Oncology
Samodzielna Pracownia Anestezjologii, Intensywnej Terapii i Leczenia Bólu
Urology and Urological Oncology

Clinical trials at this site (36)

Search interface

The assessment of bevacizumab dose equivalence in ovarian cancer Pending

2023-509659-15-00 Patients with ovarian cancer, fallopian tube cancer, pe 6
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Pending

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5
PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending

2025-523425-17-00 Proteinuric kidney diseases 4
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting

2023-508047-40-00 Ovarian cancer 5 2026-04-30
A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting

2025-522191-86-00 Focal segmental glomerulosclerosis 5 2026-04-02
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini… Recruiting

2025-521558-40-00 Pulmonary Hypertension Associated with Interstitial Lun 5 2026-02-12
A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting

2024-519343-15-00 Low-grade Upper Tract Urothelial Cancer 5 2025-10-08
A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o… Recruiting

2023-508056-19-00 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Profi 5 2025-10-02
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Ovarian cancer recurrent 5 2025-04-11
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
Optimal antiplatelet therapy in patients after coronary artery bypass grafting. Recruiting

2025-521892-30-00 Primary isolated CABG patients with stable coronary art 5 2025-11-24
Use of oral colchicine to determine restenosis in the superficial femoral artery - the COLSTENT study Recruiting

2023-508935-30-00 Lower extremity artery disease 5 2025-11-20
A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting

2024-517184-23-00 platinum-resistant advanced high-grade epithelial ovari 4 2025-10-16
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Mainten… Recruiting

2023-509755-13-00 Idiopathic steroid-sensitive nephrotic syndrome 5 2025-04-28
ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi… Recruiting

2024-513420-41-00 prematurity in neonates 10 2025-01-09
Effect of intravenous ferric carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with r… Recruiting

2024-517206-28-00 Recent myocardial infarction associated with iron defic 6 2022-09-21
A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent … Recruiting

2023-506791-27-00 pulmonary arterial hypertension 5 2022-04-22
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or… Recruiting

2023-507149-27-00 Chemotherapy-induced Thrombocytopenia in Adult subjects 5 2019-11-04
A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn… Ended

2024-510846-15-00 Chronic Kidney Disease, with or without Type 2 diabetes 4 2025-04-14
A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended

2023-507851-31-00 Immunoglobulin A Nephropathy (IgAN) 5 2024-09-23
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01